Trial Results

April 19, 2023

Trial Results: ECOG-ACRIN Research Round-Up

Summaries of recently published ECOG-ACRIN research results
February 10, 2023

Trial Results: ASH Highlights Practice-Changing Results for B-Lineage Acute Lymphoblastic Leukemia

The phase 3 E1910 clinical trial provides strong evidence for adding immunotherapy to standard front-line consolidation chemotherapy
February 10, 2023

Trial Results: ECOG-ACRIN Research Round-Up

Summaries of recently published ECOG-ACRIN research results
October 13, 2022

Trial Results: ECOG-ACRIN Completes the First Randomized Phase 3 Clinical Trial of Neoadjuvant Immunotherapy in Patients with Kidney Cancer

The phase III PROSPER RCC clinical trial demonstrated that priming the immune system with nivolumab before surgery, then continuing nivolumab, did not improve recurrence-free survival in patients with high-risk renal cell carcinoma
October 13, 2022

Trial Results: ECOG-ACRIN Research Round-Up

Summaries of recently published ECOG-ACRIN research results
August 16, 2022

NCI-MATCH precision medicine trial leads to FDA drug approval for BRAF V600E-mutated tumors

Dabrafenib/trametinib is the first and only BRAF/MEK inhibitor combination to be approved with a tumor-agnostic indication for solid tumors carrying the BRAF V600E mutation
June 21, 2022

ECOG-ACRIN Research at ASCO 2022

ECOG-ACRIN researchers presented a wide range of study results at the 2022 ASCO Annual Meeting
February 24, 2022

Trial Results: Copanlisib in Patients with PIK3CA-Mutated Tumors

The first published results of a platform trial of PIK3CA mutations across multiple tumor types appear in the Journal of Clinical Oncology. The data are from the NCI-MATCH precision medicine trial.
January 26, 2022

Trial Results: Journal of Clinical Oncology Publishes Final Results of E3311 Phase II Trial for Head and Neck Cancer

A new post-surgery approach for treating HPV-related throat cancer uses less radiation safely and spares the majority of patients from chemotherapy
December 22, 2021

ECOG-ACRIN Research at ASH 2021

Researchers with the Leukemia, Lymphoma, and Myeloma Committees presented a range of findings pertaining to treatments, patient-reported outcomes, and genomics
November 16, 2021

Trial Results: ASCO Highlights Practice-Changing Results in Melanoma

The phase 3 DREAMseq clinical trial provides strong evidence for starting treatment with combination immunotherapy then giving targeted therapy if the disease progresses in patients with BRAF V600 mutant metastatic melanoma
July 7, 2021

Trial Updates: TMIST Enrollment Hits 50,000; NCI-MATCH News; Recent Research Results

Recent ECOG-ACRIN trial updates and results